FULC

Fulcrum Therapeutics Inc

3.77

Nov 13 • 3:59 PM ET +0.09 (2.45%)

3.77

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: BHVN AXSM LTGO VNDA SPTX TNXP RAPP DWTX PRAX XENE

| Held by: VTI IWM VXF IWN FESM IBB VTWO SCHA DFAS IWC

Scroll to Statements

Index	RUT
Market Cap	287.64M
Enterprise Value	-13.17M
Income	-76.34M
Sales	0.00M
Book/sh	3.95
Cash/sh	4.03
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	55
IPO	Jul 18, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.95
P/C	0.93
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	36.19
Current Ratio	36.19
Debt/Eq	0.02
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.04
EPS next Y	-0.12
EPS next Q	-0.11
EPS this Y	49.15%
EPS next Y	80.00%
EPS next 5Y	79.61%
EPS past 3/5Y	21.49% 15.80%
Sales past 3/5Y	- -
EPS Y/Y TTM	11.50%
Sales Y/Y TTM	-100.00%
EPS Q/Q	54.22%
Sales Q/Q	-
Earnings	Aug 05
EPS/Sales Surpr.	-33.07% -

Insider Own	3.37%
Insider Trans	18.40%
Inst Own	98.22%
Inst Trans	-14.77%
ROA	-29.05%
ROE	-30.51%
ROIC	-25.28%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.59%
SMA50	0.97%
SMA200	-31.66%
Trades

Shs Outstand	76.38M
Shs Float	73.73M
Short Float	8.74%
Short Ratio	4.27
Short Interest	6.44M
52W High	15.74 -76.05%
52W Low	2.83 33.22%
Volatility	1.73% 1.85%
ATR (14)	0.08
RSI (14)	54.89
Beta	2.77
Rel Volume	0.90
Avg Volume	1.51M
Volume	1,364,458

Perf Week	1.89%
Perf Month	2.72%
Perf Quarter	-1.82%
Perf Half Y	-43.65%
Perf YTD	-66.67%
Perf Year	-57.11%
Perf 3Y	8.65%
Perf 5Y	-79.56%
Perf 10Y	-
Recom	3.00
Target Price	4.00
Prev Close	3.68
Price	3.77
Change %	2.45%

Consensus

Hold

Avg. Price Target

$4.00

Implied Upside

+6.1%

Analysts9incl. previous ratings

Rating Distribution1 Buy · 6 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 03, 2026	Downgrade	JJP Morgan	Overweight → Underweight
Jun 02, 2026	Downgrade	TTruist	Buy → Hold	$4	+6.1%
Jun 02, 2026	Downgrade	SStifel	Buy → Hold	$3	-20.4%
Jun 02, 2026	Downgrade	PPiper Sandler	Overweight → Neutral	$3	-20.4%
Jun 02, 2026	Downgrade	LLeerink Partners	Outperform → Market Perform	$4	+6.1%
Jun 02, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral	$3	-20.4%
Jan 12, 2026	Initiated	JJP Morgan	Overweight	$20	+430.5%
Nov 24, 2025	Initiated	TTruist	Buy
Jul 29, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$4 → $12	+218.3%
May 23, 2025	Upgrade	LLeerink Partners	Market Perform → Outperform	$12	+218.3%
May 15, 2025	Upgrade	CCantor Fitzgerald	Neutral → Overweight	$10	+165.3%
Sep 13, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral	$17 → $4	+6.1%
Sep 12, 2024	Downgrade	SStifel	Buy → Hold
Sep 12, 2024	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$15 → $4	+6.1%
Sep 12, 2024	Downgrade	LLeerink Partners	Outperform → Market Perform	$4	+6.1%
Sep 12, 2024	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Sep 12, 2024	Downgrade	BBofA Securities	Neutral → Underperform	$10 → $2	-46.9%
Sep 09, 2024	Upgrade	BBofA Securities	Underperform → Neutral	$5 → $10	+165.3%
May 20, 2024	Initiated	CCantor Fitzgerald	Overweight	$23	+510.1%
Mar 13, 2024	Initiated	RRBC Capital Mkts	Outperform	$14	+271.4%

Oct-12-26 10:46PM	Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders? (PR Newswire)
Oct-08-26 04:40PM	Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors (Newsfile)
Oct-06-26 06:55PM	Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights (Newsfile)
Sep-30-26 09:10AM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations (Newsfile)
Sep-25-26 07:39AM	Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders? (PR Newswire)
12:55PM	Loading…
Sep-18-26 12:55PM	Are FULC, WEAV, BWIN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-15-26 11:27AM	Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-14-26 05:20PM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Investors Who Suffered Losses (Newsfile)
Sep-10-26 06:10PM	Kaplan Fox Urges Investors of Fulcrum Therapeutics, Inc. (FULC) with Losses to Contact the Firm (Newsfile)
Sep-09-26 03:24PM	Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-04-26 02:40PM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Shareholders for Possible Securities Law Violations (Newsfile)
Sep-02-26 10:40AM	Are UTZ, ITGR, FULC Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-28-26 01:50PM	Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-27-26 05:49PM	Slate Medicines Starts Migraine Treatment Study (Exec Edge)
Aug-24-26 08:37AM	Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? (PR Newswire)
11:30AM	Loading…
Aug-19-26 11:30AM	Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm to Learn About Their Legal Rights (Newsfile)
Aug-18-26 04:56AM	Fulcrum and Slate Medicines sign merger agreement (Hospital Management)
Aug-17-26 10:10PM	Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? (PR Newswire)
12:11PM	Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies (Exec Edge)
11:15AM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Potential Violations of the Federal Securities Laws (Newsfile)
07:00AM	Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies (GlobeNewswire)
06:23AM	Slate, Fulcrum to combine in reverse merger (BioPharma Dive)
Aug-14-26 02:00PM	Kaplan Fox & Kilsheimer LLP is Investigating Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations (Newsfile)
Aug-12-26 01:30PM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors for Potential Securities Law Violations (Newsfile)
Aug-10-26 12:32PM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and Encourages Investors Who Suffered Losses to Contact the Firm (Newsfile)
Aug-05-26 12:00PM	Kaplan Fox Urges Fulcrum Therapeutics, Inc. (FULC) Investors to Contact the Firm About Possible Securities Law Violations (Newsfile)
Jun-02-26 11:04PM	Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? (Stocktwits) -51.09%
09:43AM	Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls (The Fly)
08:08AM	Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug (BioPharma Dive)
07:53AM	This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has 'No Viable Path Forward.' (Barrons.com)
05:50PM	Loading…
Jun-01-26 05:50PM	FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk (Stocktwits) -7.23%
04:05PM	Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review (GlobeNewswire)
May-08-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-26 03:02AM	Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Apr-27-26 11:08AM	Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations (InvestorsHub)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 (GlobeNewswire)
06:55AM	Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors (GlobeNewswire)
Apr-20-26 08:00AM	Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET (GlobeNewswire)
Mar-19-26 08:00AM	MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease (GlobeNewswire)
Mar-06-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-03-26 08:30AM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-25-26 10:27AM	Fulcrum Therapeutics move lower overdone, says Stifel (TipRanks)
Feb-24-26 11:47AM	Fulcrum Therapeutics Q4 Earnings Call Highlights (MarketBeat) -21.21%
09:48AM	What's Going On With Fulcrum Therapeutics Stock Tuesday? (Benzinga)
07:01AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 (GlobeNewswire)
07:00AM	Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Feb-17-26 08:00AM	Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Feb-12-26 09:55AM	Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? (Zacks)
Feb-06-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
Jan-09-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 08:00AM	Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-25 09:55AM	Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet (Zacks) -5.42%
Dec-21-25 07:31AM	Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study (Insider Monkey)
Dec-10-25 07:48AM	Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.48%
Dec-08-25 04:01PM	Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock (GlobeNewswire) +45.96% +12.39%
Dec-06-25 05:30PM	Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-05-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +45.96%
Dec-02-25 08:30AM	Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 (GlobeNewswire) -9.32%
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
Nov-19-25 04:20PM	Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged (Investor's Business Daily) +18.29%
Nov-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:45AM	Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 04:45PM	Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire) -7.21%
Oct-29-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 (GlobeNewswire) -6.40%
Oct-22-25 08:54AM	Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET (GlobeNewswire) -6.80%
Oct-14-25 07:00AM	Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire)
Oct-10-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Sep-12-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 08:00AM	Fulcrum Therapeutics to Present at Upcoming Investor Meetings (GlobeNewswire)
Aug-08-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-29-25 06:48AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 (GlobeNewswire)
06:45AM	Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-28-25 04:01PM	Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 01:17AM	Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory (Insider Monkey)
May-29-25 04:10PM	Fulcrum Therapeutics to Present at Upcoming Medical Meetings (GlobeNewswire)
08:30AM	Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-09-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77%
May-08-25 04:05PM	Fulcrum Therapeutics to Participate in Upcoming May Conferences (GlobeNewswire) +6.71%
May-02-25 03:03AM	Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... (GuruFocus.com) +28.31%
01:27AM	Q1 2025 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 01:55PM	Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript (Seeking Alpha) +13.77%
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 (GlobeNewswire)
Apr-24-25 08:00AM	Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET (GlobeNewswire)
Apr-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.55%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-04-25 04:05PM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-26-25 02:04AM	Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -10.27%
01:28AM	Q4 2024 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 (GlobeNewswire)
01:52AM	Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result (GuruFocus.com)
Feb-18-25 04:05PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET (GlobeNewswire)
Feb-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:05PM	Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-28-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why (Zacks)
Nov-26-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming December Conferences (GlobeNewswire) +11.27%
Nov-14-24 02:07AM	Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... (GuruFocus.com) -6.74%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Greg Tourangeau	former officer	Sep 02 '26	Proposed Sale	3.87	14,062	54,420		Sep 02 09:30 AM
TANG KEVIN	10% Owner	Jul 16 '26	Buy	3.56	116,671	415,349	7,030,000	Jul 20 09:10 PM
TANG KEVIN	10% Owner	Jul 17 '26	Buy	3.52	50,945	179,326	7,080,945	Jul 20 09:10 PM
TANG KEVIN	10% Owner	Jul 14 '26	Buy	3.57	129,603	462,906	6,805,952	Jul 15 07:50 PM
TANG KEVIN	10% Owner	Jul 15 '26	Buy	3.56	107,377	382,262	6,913,329	Jul 15 07:50 PM
TANG KEVIN	10% Owner	Jul 13 '26	Buy	3.54	12,966	45,900	6,676,349	Jul 15 07:50 PM
Ezekowitz Alan	Director	Jun 26 '26	Sale	3.65	18,000	65,614	10,927	Jun 30 04:30 PM
ALAN EZEKOWITZ	Director	Jun 26 '26	Proposed Sale	3.61	18,000	64,980		Jun 26 04:26 PM
Gould Robert J	Director	Feb 02 '26	Sale	10.72	15,000	160,857	454,864	Feb 04 04:10 PM
Gould Robert J	Director	Jan 02 '26	Sale	11.87	15,000	178,089	469,864	Jan 06 04:30 PM
Oltmans Curtis Gale	Chief Legal Officer	Dec 15 '25	Sale	12.92	3,452	44,600	10,252	Dec 17 04:10 PM
CURTIS G OLTMANS	Officer	Dec 15 '25	Proposed Sale	13.00	3,452	44,876		Dec 15 04:32 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Dec 08 '25	Sale	13.98	4,175,139	58,377,021	6,053,960	Dec 10 04:42 PM
RA Capital Healthcare Fund LP	10% Owner	Dec 08 '25	Proposed Sale	12.99	4,175,139	54,235,056		Dec 08 05:40 PM
Gould Robert J	Director	Nov 19 '25	Sale	11.03	15,000	165,495	484,864	Nov 21 04:15 PM
ROBERT J GOULD	Director	Nov 19 '25	Proposed Sale	9.73	45,000	437,850		Nov 19 04:20 PM

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

CEOMr. Alexander C. Sapir

CPAMr. Alan A. Musso C.M.A.

Chief Legal OfficerMr. Curtis G. Oltmans J.D.

Ph.D.Dr. Bradley E. Bernstein M.D.

FounderDr. Michael R. Green

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

FULC

Fulcrum Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.